Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Pharma takeover

- PMLiVE

Horizon looks bright as FDA panel backs eye drug teprotumumab

First alternative to surgery for proptosis

- PMLiVE

Horizon sunny as thyroid eye disease drug hits the mark

New treatment helps lessen eye bulging

- PMLiVE

Horizon swoops on Raptor to add rare disease products

Gains two new orphan medicines through the $800m deal

- PMLiVE

Allergan CEO takes issue with ‘predatory’ price increases

Saunders adds voice to drug pricing outcry saying perpetrators break “social contract”

- PMLiVE

Rebuffed Horizon tries to replace Depomed board members

But firm says latest deal 'significantly undervalues' Depomed

- PMLiVE

Horizon launches $3bn hostile bid for Depomed

Horizon wants to add Depomed’s pain therapies and CNS drugs to its products

- PMLiVE

Teva planning fresh offer for Mylan, say sources

Israeli firm has already made multiple informal bids

- PMLiVE

Receptos rejected AZ takeover bid, say sources

Sources also claim the Delaware-based firm is being chased by Gilead Sciences and Teva

Shire Basingstoke

Shire rumoured to be pursuing Actelion

Allegedly made a £12.4bn takeover bid for the Swiss biopharma

- PMLiVE

Pfizer ‘bids €1.5bn’ for CAR-T specialist Cellectis

French immuno-oncology biotech reported to be next on pharma giant's hit list

- PMLiVE

Perrigo warming to Mylan – at the right price

Perrigo has already rejected three prior bids

- PMLiVE

Perrigo rejects Mylan again as Teva bites back

There is much debate over the value of the company’s shares

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links